SCHEMBL6026005

SCHEMBL6026005

O=C(Cc1ccc(S(=O)(=O)Cl)cc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
ALDH1A1 P00352 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
PLAU P00749 1/20 0.50
HSD17B10 Q99714 1/20 0.50
STS P08842 1/20 0.49
SRD5A2 P31213 2/20 0.49
SMO Q99835 1/20 0.48
MAPK1 P28482 2/20 0.46
TRPA1 O75762 1/20 0.46
GSK3B P49841 1/20 0.46
HIF1A Q16665 1/20 0.46
S1PR5 Q9H228 1/20 0.46
RECQL P46063 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HSD11B1 P28845 1/20 0.45
CES1 P23141 2/20 0.44
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512363 0.93 MAPT (0.64) MAPTL3MBTL1ALDH1A1TDP1PLAU
SCHEMBL2500404 0.86 PRMT1 (0.54) MAPTL3MBTL1TDP1PLAUSTS
SCHEMBL11033528 0.84 SMN1; SMN2 (0.52) MAPTL3MBTL1TDP1PLAUSTS
SCHEMBL7199268 0.83 MAPT (0.67) MAPTL3MBTL1ALDH1A1TDP1PLAU
SCHEMBL6341279 0.83 PTGS2 (0.51) MAPTL3MBTL1PLAUSTSSRD5A2
SCHEMBL6026667 0.83 CA1 (0.61) PLAUSTSKDM4EKMT2ASMN1; SMN2
SCHEMBL4282905 0.81 MAPT (0.70) MAPTL3MBTL1ALDH1A1TDP1PLAU
Sulfuric Acid SCHEMBL4404554 0.80 MAPT (0.59) MAPTL3MBTL1ALDH1A1TDP1PLAU
SCHEMBL164742 0.80 CA2 (0.54) MAPTALDH1A1TDP1HSD17B10HIF1A
SCHEMBL24800 0.79 MAPT (0.73) MAPTL3MBTL1ALDH1A1TDP1PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6998415-B2 Pyrazolyl derivatives; antiinflammatory agents for inflammation; antiallergens for asthma PHARMACIA CORPORATION (US) 2006-02-14 US disclosed
WO-2005123701-A1 METHOD FOR THE PREPARATION OF DIARYLISOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES PHARMACIA CORPORATION (US) 2005-12-29 WO disclosed
US-20040147565-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors G.D. SEARLE & CO. 2004-07-29 US disclosed
EP-0828736-B1 SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS SEARLE & CO (US) 2003-07-30 EP disclosed
EP-0995747-B1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors SEARLE & CO (US) 2002-08-07 EP disclosed
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0995747-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors G.D. SEARLE & CO. (US) 2000-04-26 EP disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed
WO-1996036617-A1 SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147565-A1 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors ALOX5, ALOX12, ALOX15 MAPT 4789/4885L3MBTL1 3923/4885ALDH1A1 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.